港股市场上，荣昌生物（09995）今日盘中大涨7.75%，截至发稿，报109.4港元，成交额达3.57亿港元。该股的强劲表现引起了投资者的广泛关注。
消息面上，荣昌生物近期传出利好消息。9月28日，国家药品监督管理局药品审评中心（CDE）官网显示，荣昌生物的新药泰它西普拟纳入优先审评品种，用于治疗具有进展风险的原发性免疫球蛋白A（IgA）肾病成人患者。此前，该公司已于8月27日宣布，泰它西普治疗IgA肾病的国内III期研究达成A阶段的主要终点。研究结果显示，与安慰剂组相比，泰它西普组患者在治疗39周时24小时尿蛋白肌酐比值（UPCR）降低了55%，展现出显著的临床效果。
值得注意的是，今日港股市场上多只生物技术股呈现上涨态势。除荣昌生物外，晶泰控股涨超8%，来凯医药涨超7%，映恩生物涨超6%，再鼎医药和药明康德均涨超1%。这一趋势表明，投资者对生物科技行业的前景保持乐观态度，而荣昌生物作为该领域的重要参与者，其股价表现更是受到市场的青睐。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.